Schonfeld Strategic Advisors LLC Cyma Bay Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

$14.6 Billion
Q2 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $1.89 Million - $3.06 Million	173,938 Added 246.09%	244,620 $3.65 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $527,994 - $773,967	70,682 New	70,682 $773,000
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $391,819 - $762,952	121,683 New	121,683 $762,000
Q3 2021 Nov 16, 2021	SELL	$3.47 - $4.42 $52,060 - $66,313	-15,003 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.94 - $4.92 $59,111 - $73,814	15,003 New	15,003 $65,000
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $2.87 Million - $4.53 Million	-501,368 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.32 - $7.24 $1.4 Million - $3.05 Million	420,986 Added 523.73%	501,368 $4,000
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $34,026 - $102,561	24,132 Added 42.9%	80,382 $281,000
Q1 2020 May 15, 2020	BUY	$1.25 - $2.02 $70,312 - $113,625	56,250 New	56,250 $83,000
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $103,474 - $461,354	-77,800 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $2.53 Million - $3.56 Million	-494,400 Reduced 86.4%	77,800 $398,000
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $1.63 Million - $3.67 Million	268,800 Added 88.6%	572,200 $4.1 Million
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $2.29 Million - $3.77 Million	281,200 Added 1266.67%	303,400 $4.03 Million
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $53,628 - $96,268	8,200 Added 58.57%	22,200 $175,000
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $130,560 - $174,240	-12,000 Reduced 46.15%	14,000 $156,000
Q2 2018 Aug 14, 2018	BUY	$10.66 - $14.38 $277,160 - $373,880	26,000 New	26,000 $349,000
Q4 2017 Feb 14, 2018	SELL	$7.67 - $9.31 $263,924 - $320,357	-34,410 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $204,739 - $284,226	34,410	34,410 $278,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account